Literature DB >> 17786352

The activity of Selol in multidrug-resistant and sensitive human leukemia cells.

Piotr Suchocki1, Irena Misiewicz, Katarzyna Skupinska, Karolina Waclawek, Zbigniew Fijalek, Teresa Kasprzycka-Guttman.   

Abstract

Selol is a mixture of selenitetriglycerides synthesized from sunflower oil. As it contains the element selenium in its structure, it is suspected to exhibit chemopreventive and anticancer activity. In this study, the ability of Selol to inhibit cell proliferation and to induce apoptosis was investigated. Three cell lines were used: leukemia HL-60 cell line and multidrug-resistant HL-60/Dox (resistant to doxorubicin) and HL-60/Vinc (resistant to vincristine). Selol was shown to reduce the cell number as a result of treatment with increasing concentrations. For selected concentrations the evidence of apoptosis (changes in mitochondrial potential and caspase activity) was investigated, as well as changes in lysosome distribution. The study has shown that Selol overcame the cell resistance, as doxorubicin-resistant cells were more sensitive towards Selol than sensitive cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786352

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Authors:  Cody P Coyne; Toni Jones; Andrzej Sygula; John Bailey; Lesya Pinchuk
Journal:  J Cancer Ther       Date:  2011-03

2.  Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy.

Authors:  Luciana L C Estevanato; Jaqueline R Da Silva; André M Falqueiro; Ewa Mosiniewicz-Szablewska; Piotr Suchocki; Antônio C Tedesco; Paulo C Morais; Zulmira G M Lacava
Journal:  Int J Nanomedicine       Date:  2012-10-05

3.  PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells.

Authors:  Ludmilla Regina de Souza; Luis Alexandre Muehlmann; Mayara Simonelly Costa Dos Santos; Rayane Ganassin; Rosana Simón-Vázquez; Graziella Anselmo Joanitti; Ewa Mosiniewicz-Szablewska; Piotr Suchocki; Paulo César Morais; África González-Fernández; Ricardo Bentes Azevedo; Sônia Nair Báo
Journal:  J Nanobiotechnology       Date:  2014-08-23       Impact factor: 10.435

4.  Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2015-01

Review 5.  Selenium Compounds as Novel Potential Anticancer Agents.

Authors:  Dominika Radomska; Robert Czarnomysy; Dominik Radomski; Krzysztof Bielawski
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 6.208

6.  Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol.

Authors:  Jadwiga Dudkiewicz-Wilczyńska; Agnieszka Grabowska; Iza Książek; Karolina Sitarz; Piotr Suchocki; Elżbieta Anuszewska
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03

7.  The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions.

Authors:  Lidia Śliwka; Katarzyna Wiktorska; Piotr Suchocki; Małgorzata Milczarek; Szymon Mielczarek; Katarzyna Lubelska; Tomasz Cierpiał; Piotr Łyżwa; Piotr Kiełbasiński; Anna Jaromin; Anna Flis; Zdzisław Chilmonczyk
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.